Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
Understanding the process and implementing proper procedures is the key to ensuring compliance when reporting such events
How three companies are addressing screening challenges with tests that help improve chances of early detection